HU228826B1 - Use of pyrrole derivatives for making pharmaceutical compositions - Google Patents

Use of pyrrole derivatives for making pharmaceutical compositions Download PDF

Info

Publication number
HU228826B1
HU228826B1 HU0201394A HUP0201394A HU228826B1 HU 228826 B1 HU228826 B1 HU 228826B1 HU 0201394 A HU0201394 A HU 0201394A HU P0201394 A HUP0201394 A HU P0201394A HU 228826 B1 HU228826 B1 HU 228826B1
Authority
HU
Hungary
Prior art keywords
compound
disorder
pharmaceutically acceptable
anxiety
compounds
Prior art date
Application number
HU0201394A
Other languages
English (en)
Hungarian (hu)
Inventor
Cathryn Montgomery Clary
Beek Jeroen Bernard Van
Perry Steven Eisman
Sean David Donevan
Atul Chandra Pande
Richard James Kavousssi
Lyou-Fu Ma
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HU0201394D0 publication Critical patent/HU0201394D0/hu
Publication of HUP0201394A2 publication Critical patent/HUP0201394A2/hu
Publication of HUP0201394A3 publication Critical patent/HUP0201394A3/hu
Publication of HU228826B1 publication Critical patent/HU228826B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0201394A 2001-04-30 2002-04-29 Use of pyrrole derivatives for making pharmaceutical compositions HU228826B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30

Publications (4)

Publication Number Publication Date
HU0201394D0 HU0201394D0 (enExample) 2002-06-29
HUP0201394A2 HUP0201394A2 (hu) 2002-12-28
HUP0201394A3 HUP0201394A3 (en) 2003-12-29
HU228826B1 true HU228826B1 (en) 2013-05-28

Family

ID=23103396

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201394A HU228826B1 (en) 2001-04-30 2002-04-29 Use of pyrrole derivatives for making pharmaceutical compositions

Country Status (20)

Country Link
US (2) US7026332B2 (enExample)
EP (2) EP1642576B1 (enExample)
JP (1) JP2002326934A (enExample)
KR (1) KR20020084413A (enExample)
CN (1) CN1384104A (enExample)
AT (2) ATE331513T1 (enExample)
AU (1) AU783516B2 (enExample)
CA (1) CA2383599C (enExample)
CY (1) CY1109129T1 (enExample)
DE (2) DE60231568D1 (enExample)
DK (1) DK1642576T3 (enExample)
ES (2) ES2323646T3 (enExample)
HU (1) HU228826B1 (enExample)
IL (2) IL149280A0 (enExample)
MY (1) MY129575A (enExample)
NZ (1) NZ518615A (enExample)
PL (2) PL207725B1 (enExample)
PT (1) PT1642576E (enExample)
TW (1) TWI302455B (enExample)
ZA (1) ZA200203347B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
WO2005105061A2 (en) * 2004-04-14 2005-11-10 Indevus Pharmaceuticals, Inc. Transdermal patch
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2012116288A1 (en) * 2011-02-25 2012-08-30 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) * 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) * 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
ATE331513T1 (de) 2006-07-15
PL390683A1 (pl) 2010-05-24
CA2383599C (en) 2006-10-31
ES2323646T3 (es) 2009-07-22
PL207738B1 (pl) 2011-01-31
EP1254660A3 (en) 2003-03-26
PL207725B1 (pl) 2011-01-31
HUP0201394A2 (hu) 2002-12-28
DK1642576T3 (da) 2009-04-14
EP1642576A3 (en) 2007-01-10
AU783516B2 (en) 2005-11-03
PT1642576E (pt) 2009-05-21
US7553847B2 (en) 2009-06-30
CN1384104A (zh) 2002-12-11
DE60212757T2 (de) 2007-06-28
DE60212757D1 (de) 2006-08-10
CA2383599A1 (en) 2002-10-30
CY1109129T1 (el) 2014-07-02
AU2760902A (en) 2002-10-31
IL149280A0 (en) 2002-11-10
EP1254660B1 (en) 2006-06-28
ATE424820T1 (de) 2009-03-15
JP2002326934A (ja) 2002-11-15
US20030022915A1 (en) 2003-01-30
PL353681A1 (en) 2002-11-04
MY129575A (en) 2007-04-30
HK1094307A1 (en) 2007-03-30
ZA200203347B (en) 2003-11-26
EP1254660A2 (en) 2002-11-06
US7026332B2 (en) 2006-04-11
IL204665A (en) 2011-05-31
EP1642576B1 (en) 2009-03-11
TWI302455B (en) 2008-11-01
HUP0201394A3 (en) 2003-12-29
NZ518615A (en) 2004-03-26
ES2267943T3 (es) 2007-03-16
US20060128746A1 (en) 2006-06-15
KR20020084413A (ko) 2002-11-07
DE60231568D1 (de) 2009-04-23
EP1642576A2 (en) 2006-04-05
HU0201394D0 (enExample) 2002-06-29

Similar Documents

Publication Publication Date Title
US20050004106A1 (en) Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics
US20240024340A1 (en) Compositions and Methods For Treating Migraine
ES2260195T3 (es) Metodos de producir (r)-y (s)-didesmetil-sibutramina opticamente pura.
WO2015089111A1 (en) Novel methods
HU228826B1 (en) Use of pyrrole derivatives for making pharmaceutical compositions
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
US20230181572A1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
RU2238084C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
HK1094307B (en) Use of pyrrole derivatives to combat anxiety
HK1050361A (en) Methods, kits and compositions for using pyrrole derivatives
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40067131A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
Tablets et al. PrQ-CITALOPRAM
Tablet et al. Submission Control No: 201507
Tablets et al. H9R 4Z7
Tablet et al. PrNTP-CITALOPRAM
Compulsions Convergence Mito r
CA2617420A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees